Pulmonx Q2 2023 Earnings Report $6.10 +0.04 (+0.66%) As of 01/23/2025 04:00 PM Eastern Earnings HistoryForecast Pulmonx EPS ResultsActual EPS-$0.43Consensus EPS -$0.43Beat/MissMet ExpectationsOne Year Ago EPS-$0.40Pulmonx Revenue ResultsActual Revenue$17.20 millionExpected Revenue$15.86 millionBeat/MissBeat by +$1.34 millionYoY Revenue Growth+23.30%Pulmonx Announcement DetailsQuarterQ2 2023Date8/2/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseLUNG Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Pulmonx Earnings HeadlinesPulmonx director French Glendon E. III sells shares worth $29,625January 22 at 3:45 AM | msn.comComparing Biotricity (NASDAQ:BTCY) & Pulmonx (NASDAQ:LUNG)January 18, 2025 | americanbankingnews.comGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of a lifetime! January 24, 2025 | Crypto 101 Media (Ad)Analysts Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $12.75January 15, 2025 | americanbankingnews.comPulmonx (LUNG) was downgraded to a Hold Rating at CitiDecember 17, 2024 | markets.businessinsider.comPulmonx (LUNG) Gets a Buy from Lake StreetDecember 12, 2024 | markets.businessinsider.comSee More Pulmonx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email. Email Address About PulmonxPulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.View Pulmonx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025)HCA Healthcare (1/24/2025)AT&T (1/27/2025)Starbucks (1/28/2025)PACCAR (1/28/2025)Intuitive Surgical (1/28/2025)General Motors (1/28/2025)RTX (1/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
